Drugs / Amnion Membrane Powder
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03754218 | Dec 2019 → Nov 2023 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07680023 | Oct 2026 → Oct 2027 expected | — | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amnion Membrane Powder | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03754218 ↗ |
| Modality | Other / unclassified | “The proposed sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.” NCT07680023 ↗ |
| Route | Topical | “for topical application” NCT03754218 ↗ |